当前蛋白身份:P28062 重新检索
本组结构的主要差异维度
构建体不同 组装状态不同 配体/离子不同 实验方法不同 实验环境不同 结构质量指标不同

差异标签只比较当前检索结果;所有PDB和assembly原始记录仍分别保留。

相关结构差异明细

一行代表一个 PDB 条目中的一个 biological assembly;同一蛋白的多个单体会分别列出。

PDB 条目 Assembly / 聚集状态 构建体 突变与修饰 配体、离子与非聚合物 实验方法 实验环境 结构质量
5L5A Yeast 20S proteasome with human beta5i (1-138; R57T) 提交 2016-05-28 Assembly 1 信息不足 异源复合物;蛋白 × 28 PDB 声明:28-meric(28) 与蛋白数一致
链 K 73–210(138 aa)
链 Y 73–210(138 aa)
未记录 MG MAGNESIUM ION × 10 CL CHLORIDE ION × 2 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 6.8;293 K;20 mM MgAC2, 13% MPD, 0.1 M MES
分辨率 2.40 Å R-free 0.219
5L5B Yeast 20S proteasome with human beta5i (1-138) and human beta6 (97-111; 118-133) 提交 2016-05-28 Assembly 1 信息不足 异源复合物;蛋白 × 28 PDB 声明:28-meric(28) 与蛋白数一致
链 K 73–210(138 aa)
链 Y 73–210(138 aa)
未记录 MG MAGNESIUM ION × 9 CL CHLORIDE ION × 4 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 6.8;293 K;20 mM MgAC2, 13% MPD, 0.1 M MES
分辨率 2.80 Å R-free 0.211
5L5D Yeast 20S proteasome with human beta5i (1-138) and human beta6 (97-111; 118-133) in complex with ONX 0914 提交 2016-05-28 Assembly 1 信息不足 异源复合物;蛋白 × 28 PDB 声明:28-meric(28) 与蛋白数一致
链 K 73–210(138 aa)
链 Y 73–210(138 aa)
未记录 MG MAGNESIUM ION × 8 CL CHLORIDE ION × 2 04C 1,2,4-trideoxy-4-methyl-2-{[N-(morpholin-4-ylacetyl)-L-alanyl-O-methyl-L-tyrosyl]amino}-1-phenyl-D-xylitol × 6 MES 2-(N-MORPHOLINO)-ETHANESULFONIC ACID × 3 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 6.8;293 K;20 mM MgAC2, 13% MPD, 0.1 M MES
分辨率 2.80 Å R-free 0.221
5L5E Yeast 20S proteasome with human beta5i (1-138) and human beta6 (97-111; 118-133) in complex with carfilzomib 提交 2016-05-28 Assembly 1 信息不足 异源复合物;蛋白 × 28 PDB 声明:28-meric(28) 与蛋白数一致
链 K 73–210(138 aa)
链 Y 73–210(138 aa)
未记录 MG MAGNESIUM ION × 7 CL CHLORIDE ION × 4 3BV N-{(2S)-2-[(morpholin-4-ylacetyl)amino]-4-phenylbutanoyl}-L-leucyl-N-[(2R,3S,4S)-1,3-dihydroxy-2,6-dimethylheptan-4-yl]-L-phenylalaninamide × 6 MES 2-(N-MORPHOLINO)-ETHANESULFONIC ACID × 2 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 6.8;293 K;20 mM MgAC2, 13% MPD, 0.1 M MES
分辨率 2.90 Å R-free 0.227
5L5F Yeast 20S proteasome with human beta5i (1-138) and human beta6 (97-111; 118-133) in complex with bortezomib 提交 2016-05-28 Assembly 1 信息不足 异源复合物;蛋白 × 28 PDB 声明:28-meric(28) 与蛋白数一致
链 K 73–210(138 aa)
链 Y 73–210(138 aa)
未记录 MG MAGNESIUM ION × 8 CL CHLORIDE ION × 4 BO2 N-[(1R)-1-(DIHYDROXYBORYL)-3-METHYLBUTYL]-N-(PYRAZIN-2-YLCARBONYL)-L-PHENYLALANINAMIDE × 6 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 6.8;293 K;20 mM MgAC2, 13% MPD, 0.1 M MES
分辨率 2.50 Å R-free 0.228
5L5H Yeast 20S proteasome with human beta5i (1-138) and human beta6 (97-111; 118-133) in complex with PR-924 提交 2016-05-28 Assembly 1 信息不足 异源复合物;蛋白 × 28 PDB 声明:28-meric(28) 与蛋白数一致
链 K 73–210(138 aa)
链 Y 73–210(138 aa)
未记录 MG MAGNESIUM ION × 9 CL CHLORIDE ION × 2 39V N-[(3-methyl-1H-inden-2-yl)carbonyl]-D-alanyl-N-[(2S,4R)-5-hydroxy-4-methyl-3-oxo-1-phenylpentan-2-yl]-L-tryptophanamide × 2 MES 2-(N-MORPHOLINO)-ETHANESULFONIC ACID × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 6.8;293 K;20 mM MgAC2, 13% MPD, 0.1 M MES
分辨率 2.60 Å R-free 0.216
5L5I Yeast 20S proteasome with human beta5i (1-138) and human beta6 (97-111; 118-133) in complex with epoxyketone inhibitor 9 提交 2016-05-28 Assembly 1 信息不足 异源复合物;蛋白 × 28 PDB 声明:28-meric(28) 与蛋白数一致
链 K 73–210(138 aa)
链 Y 73–210(138 aa)
未记录 MG MAGNESIUM ION × 8 CL CHLORIDE ION × 2 38X N-[(3-methyl-1H-inden-2-yl)carbonyl]-D-alanyl-N-[(2S,4R)-1-cyclohexyl-5-hydroxy-4-methyl-3-oxopentan-2-yl]-L-tryptophanamide × 2 MES 2-(N-MORPHOLINO)-ETHANESULFONIC ACID × 2 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 6.8;293 K;20 mM MgAC2, 13% MPD, 0.1 M MES
分辨率 2.90 Å R-free 0.210
5L5J Yeast 20S proteasome with human beta5i (1-138) and human beta6 (97-111; 118-133) in complex with epoxyketone inhibitor 14 提交 2016-05-28 Assembly 1 信息不足 异源复合物;蛋白 × 28 PDB 声明:28-meric(28) 与蛋白数一致
链 K 73–210(138 aa)
链 Y 73–210(138 aa)
未记录 MG MAGNESIUM ION × 8 CL CHLORIDE ION × 2 6N5 ~{N}-[(2~{S})-1-[[(2~{S})-3-(4-methoxyphenyl)-1-[[(2~{S},3~{S},4~{R})-4-methyl-3,5-bis(oxidanyl)-1-phenyl-pentan-2-yl]amino]-1-oxidanylidene-propan-2-yl]amino]-1-oxidanylidene-propan-2-yl]-1-methyl-5~{H}-indene-2-carboxamide × 4 MES 2-(N-MORPHOLINO)-ETHANESULFONIC ACID × 2 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 6.8;293 K;20 mM MgAC2, 13% MPD, 0.1 M MES
分辨率 2.90 Å R-free 0.200
5L5O Yeast 20S proteasome with human beta5i (1-138) and human beta6 (97-111; 118-133) in complex with epoxyketone inhibitor 16 提交 2016-05-28 Assembly 1 信息不足 异源复合物;蛋白 × 28 PDB 声明:28-meric(28) 与蛋白数一致
链 K 73–210(138 aa)
链 Y 73–210(138 aa)
未记录 MG MAGNESIUM ION × 8 CL CHLORIDE ION × 2 79P (2~{S})-3-(1~{H}-indol-3-yl)-~{N}-[(2~{S},3~{S},4~{R})-4-methyl-3,5-bis(oxidanyl)-1-phenyl-pentan-2-yl]-2-[[(2~{R})-2-(2-morpholin-4-ylethanoylamino)propanoyl]amino]propanamide × 4 MES 2-(N-MORPHOLINO)-ETHANESULFONIC ACID × 2 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 6.8;293 K;20 mM MgAC2, 13% MPD, 0.1 M MES
分辨率 2.60 Å R-free 0.214
5L5P Yeast 20S proteasome with human beta5i (1-138) and human beta6 (97-111; 118-133) in complex with epoxyketone inhibitor 17 提交 2016-05-28 Assembly 1 信息不足 异源复合物;蛋白 × 28 PDB 声明:28-meric(28) 与蛋白数一致
链 K 73–210(138 aa)
链 Y 73–210(138 aa)
未记录 MG MAGNESIUM ION × 9 CL CHLORIDE ION × 2 79L (2~{S})-3-(4-methoxyphenyl)-~{N}-[(2~{S},3~{S},4~{R})-4-methyl-3,5-bis(oxidanyl)-1-phenyl-pentan-2-yl]-2-[[(2~{R})-2-(2-morpholin-4-ylethanoylamino)propanoyl]amino]propanamide × 4 MES 2-(N-MORPHOLINO)-ETHANESULFONIC ACID × 2 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 6.8;293 K;20 mM MgAC2, 13% MPD, 0.1 M MES
分辨率 2.80 Å R-free 0.207
5L5Q Yeast 20S proteasome with human beta5i (1-138) and human beta6 (97-111; 118-133) in complex with epoxyketone 18 提交 2016-05-28 Assembly 1 信息不足 异源复合物;蛋白 × 28 PDB 声明:28-meric(28) 与蛋白数一致
链 K 73–210(138 aa)
链 Y 73–210(138 aa)
未记录 MG MAGNESIUM ION × 8 CL CHLORIDE ION × 2 6NV ~{N}-[(2~{R})-1-[[(2~{S})-3-(4-methoxyphenyl)-1-[[(2~{S},3~{S},4~{R})-4-methyl-3,5-bis(oxidanyl)-1-phenyl-pentan-2-yl]amino]-1-oxidanylidene-propan-2-yl]amino]-1-oxidanylidene-propan-2-yl]-1-methyl-5~{H}-indene-2-carboxamide × 2 MES 2-(N-MORPHOLINO)-ETHANESULFONIC ACID × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 6.8;293 K;20 mM MgAC2, 13% MPD, 0.1 M MES
分辨率 2.80 Å R-free 0.210
5L5R Yeast 20S proteasome with human beta5i (1-138;V31M) and human beta6 (97-111; 118-133) 提交 2016-05-28 Assembly 1 信息不足 异源复合物;蛋白 × 28 PDB 声明:28-meric(28) 与蛋白数一致
链 K 73–210(138 aa)
链 Y 73–210(138 aa)
未记录 MG MAGNESIUM ION × 8 CL CHLORIDE ION × 2 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 6.8;293 K;20 mM MgAC2, 13% MPD, 0.1 M MES
分辨率 2.90 Å R-free 0.221
5L5S Yeast 20S proteasome with human beta5i (1-138; V31M) and human beta6 (97-111; 118-133) in complex with PR-924 提交 2016-05-28 Assembly 1 信息不足 异源复合物;蛋白 × 28 PDB 声明:28-meric(28) 与蛋白数一致
链 K 73–210(138 aa)
链 Y 73–210(138 aa)
未记录 MG MAGNESIUM ION × 9 CL CHLORIDE ION × 2 39V N-[(3-methyl-1H-inden-2-yl)carbonyl]-D-alanyl-N-[(2S,4R)-5-hydroxy-4-methyl-3-oxo-1-phenylpentan-2-yl]-L-tryptophanamide × 2 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 6.8;293 K;20 mM MgAC2, 13% MPD, 0.1 M MES
分辨率 2.60 Å R-free 0.211
5L5T Yeast 20S proteasome with human beta5i (1-138; V31M) and human beta6 (97-111; 118-133) in complex with epoxyketone inhibitor 16 提交 2016-05-28 Assembly 1 信息不足 异源复合物;蛋白 × 28 PDB 声明:28-meric(28) 与蛋白数一致
链 K 73–210(138 aa)
链 Y 73–210(138 aa)
未记录 MG MAGNESIUM ION × 8 CL CHLORIDE ION × 2 MES 2-(N-MORPHOLINO)-ETHANESULFONIC ACID × 1 79P (2~{S})-3-(1~{H}-indol-3-yl)-~{N}-[(2~{S},3~{S},4~{R})-4-methyl-3,5-bis(oxidanyl)-1-phenyl-pentan-2-yl]-2-[[(2~{R})-2-(2-morpholin-4-ylethanoylamino)propanoyl]amino]propanamide × 2 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 6.8;293 K;20 mM MgAC2, 13% MPD, 0.1 M MES
分辨率 2.90 Å R-free 0.195
5L5U Yeast 20S proteasome with human beta5i (1-138; V31M) and human beta6 (97-111; 118-133) in complex with epoxyketone inhibitor 17 提交 2016-05-28 Assembly 1 信息不足 异源复合物;蛋白 × 28 PDB 声明:28-meric(28) 与蛋白数一致
链 K 73–210(138 aa)
链 Y 73–210(138 aa)
未记录 MG MAGNESIUM ION × 11 CL CHLORIDE ION × 2 04C 1,2,4-trideoxy-4-methyl-2-{[N-(morpholin-4-ylacetyl)-L-alanyl-O-methyl-L-tyrosyl]amino}-1-phenyl-D-xylitol × 4 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 6.8;293 K;20 mM MgAC2, 13% MPD, 0.1 M MES
分辨率 2.60 Å R-free 0.211
5L5V 'Yeast 20S proteasome with human beta5i (1-138; V31M) and human beta6 (97-111; 118-133) in complex with epoxyketone inhibitor 18 提交 2016-05-28 Assembly 1 信息不足 异源复合物;蛋白 × 28 PDB 声明:28-meric(28) 与蛋白数一致
链 K 73–210(138 aa)
链 Y 73–210(138 aa)
未记录 MG MAGNESIUM ION × 9 CL CHLORIDE ION × 2 6NV ~{N}-[(2~{R})-1-[[(2~{S})-3-(4-methoxyphenyl)-1-[[(2~{S},3~{S},4~{R})-4-methyl-3,5-bis(oxidanyl)-1-phenyl-pentan-2-yl]amino]-1-oxidanylidene-propan-2-yl]amino]-1-oxidanylidene-propan-2-yl]-1-methyl-5~{H}-indene-2-carboxamide × 2 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 6.8;293 K;20 mM MgAC2, 13% MPD, 0.1 M MES
分辨率 2.70 Å R-free 0.208
5LTT Yeast 20S proteasome with human beta5i (1-138; R57T)in complex with PR-924 提交 2016-09-07 Assembly 1 信息不足 异源复合物;蛋白 × 28 PDB 声明:28-meric(28) 与蛋白数一致
链 K 73–210(138 aa)
链 Y 73–210(138 aa)
未记录 MG MAGNESIUM ION × 8 CL CHLORIDE ION × 2 39V N-[(3-methyl-1H-inden-2-yl)carbonyl]-D-alanyl-N-[(2S,4R)-5-hydroxy-4-methyl-3-oxo-1-phenylpentan-2-yl]-L-tryptophanamide × 2 MES 2-(N-MORPHOLINO)-ETHANESULFONIC ACID × 2 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 6.8;293 K;20 mM MgAC2, 13% MPD, 0.1 M MES
分辨率 2.70 Å R-free 0.247
5M2B Yeast 20S proteasome with human beta5i (1-138) and human beta6 (97-111; 118-133) in complex with thiazole based inhibitor Ro19 提交 2016-10-12 Assembly 1 信息不足 异源复合物;蛋白 × 28 PDB 声明:28-meric(28) 与蛋白数一致
链 K 73–210(138 aa)
链 Y 73–210(138 aa)
未记录 MG MAGNESIUM ION × 7 CL CHLORIDE ION × 4 7DX (2~{S})-2-cyclohexyl-4-oxidanylidene-4-[[7-(4-phenyl-1,3-thiazol-2-yl)quinolin-2-yl]amino]butanoic acid × 2 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 6.8;293 K;20 mM MgAC2, 13% MPD, 0.1 M MES
分辨率 2.70 Å R-free 0.218
6AVO Cryo-EM structure of human immunoproteasome with a novel noncompetitive inhibitor that selectively inhibits activated lymphocytes 提交 2017-09-04 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 28 PDB 声明:28-meric(28) 与蛋白数一致
链 C 73–276(204 aa)
链 D 73–276(204 aa)
未记录 BZ7 N~1~-{2-[([1,1'-biphenyl]-3-carbonyl)amino]ethyl}-N~4~-tert-butyl-N~2~-(3-phenylpropanoyl)-L-aspartamide × 2 ELECTRON MICROSCOPY
cryo-EM缓冲液 pH 8
cryo-EM玻璃化条件 冷冻剂 ETHANE
分辨率 3.80 Å
6E5B Human Immunoproteasome 20S particle in complex with compound 1 提交 2018-07-19 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 28 PDB 声明:28-meric(28) 与蛋白数一致
链 K 1–276(276 aa)
链 Y 1–276(276 aa)
未记录 SCN THIOCYANATE ION × 3 NA SODIUM ION × 12 HUJ [(1R)-3-methyl-1-[[1-[2-[(2,3,4-trimethoxyphenyl)carbonylamino]ethyl]-1,2,3-triazol-4-yl]carbonylamino]butyl]-tris(oxidanyl)boron × 4 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;293 K;39% (v/v) 2-methyl-2,4-pentanediol (MPD), 0.2M sodium thiocyanate
分辨率 2.77 Å R-free 0.291
7AWE HUMAN IMMUNOPROTEASOME 20S PARTICLE IN COMPLEX WITH [(1R)-2-(1-benzofuran-3-yl)-1-{[(1S,2R,4R)-7-oxabicyclo[2.2.1]heptan-2-yl]formamido}ethyl]boronic acid 提交 2020-11-06 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 28 PDB 声明:28-meric(28) 与蛋白数一致
链 L 73–275(203 aa)
链 Z 73–275(203 aa)
未记录 NA SODIUM ION × 13 SCN THIOCYANATE ION × 11 S5K [(1R)-2-(1-benzofuran-3-yl)-1-{[(1S,2R,4R)-7-oxabicyclo[2.2.1]heptan-2-yl]formamido}ethyl]boronic acid × 4 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7.6;291 K;42 % MPD, 0.20 M NaSCN
分辨率 2.29 Å R-free 0.214
7B12 HUMAN IMMUNOPROTEASOME 20S PARTICLE IN COMPLEX WITH [2-(3-ethylphenyl)-1-[(2S)-3-phenyl-2-[(pyrazin-2-yl)formamido]propanamido]ethyl]boronic acid 提交 2020-11-23 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 28 PDB 声明:28-mer(28) 与蛋白数一致
链 L 73–275(203 aa)
链 Z 73–275(203 aa)
未记录 SO4 SULFATE ION × 5 NA SODIUM ION × 6 SKN ((R)-2-(3-ethylphenyl)-1-((S)-3-phenyl-2-(pyrazine-2-carboxamido)propanamido)ethyl)boronic acid × 6 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7.6;291 K;42 % MPD, 0.20 M NaSCN,
分辨率 2.43 Å R-free 0.225